This product is for research use only, not for human use. We do not sell to patients.

Size | Price | Stock |
---|---|---|
250mg | $100 | In Stock |
500mg | $160 | In Stock |
1g | $270 | In Stock |
2g | $450 | In Stock |
Cat #: V3156 CAS #: 1009119-65-6 Purity ≥ 99%
Description: Daclatasvir dihydrochloride (BMS790052; EBP883; BMS-790052; EBP-883; Daklinza ), the dihydrochloride salt of Daclatasvir, is a novel, highly potent and selective HCV NS5A protease inhibitor that has been approved in 2014 in EU for use in combination with sofosbuvir for the treatment of hepatitis C (HCV) by causing a decrease in serum HCV RNA levels. With an EC50 of 9–50 pM, it inhibits the HCV NS5A protease.
Publications Citing InvivoChem Products
Product Promise

- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 738.88 |
---|---|
Molecular Formula | C40H52N8Cl2O6 |
CAS No. | 1009119-65-6 |
Storage | Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Synonyms | BMS-790052; BMS 790052; EBP 883;EBP-883; EBP883; BMS790052; Daclatasvir 2HCl; Daclatasvir HCl; EBP-883; Daclatasvir 2HCl; Daklinza; Daclatasvir (dihydrochloride); Daclatasvir dihydrochloride; Daklinza (trade name) |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 1.3534 mL | 6.7670 mL | 13.5340 mL | 27.0680 mL |
5mM | 0.2707 mL | 1.3534 mL | 2.7068 mL | 5.4136 mL |
10mM | 0.1353 mL | 0.6767 mL | 1.3534 mL | 2.7068 mL |
20mM | 0.0677 mL | 0.3383 mL | 0.6767 mL | 1.3534 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.